Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.
Pharma & Biotech
Pharma & Biotech
Can a global trials map help fix spondyloarthritis’s fragmented development landscape?
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.